Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
l phenylalanine/sarcoma
Link salvestatakse lõikelauale
Leht 1 alates 27 tulemused
Use of [123I]-2-iodo-L-phenylalanine as a tumor imaging agent in two dogs with synovial cell sarcoma.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
[123I]-iodo-L-phenylalanine was successfully evaluated for gamma camera imaging in vivo in tumor-bearing athymic mice and in humans with brain tumors. Here, we report the use of this tracer in two dogs with synovial cell sarcoma of the tarsus. [123I]-iodo-L-phenylalanine was quantitatively prepared
Human meningeal sarcoma heterotransplants in Nu/Nu mice treated with L-phenylalanine mustard (L-PAM) and dianhydrogalactitol (DAG).
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The clinical characteristics and response to therapy of a patient with meningeal sarcoma, one of four patients over a twenty-five year period at Memorial Sloan-Kettering Cancer Center, are described. The light and electron microscopic characteristics of the primary tumor and as a heterotransplant in
Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a
L-PHENYLALANINE MUSTARD AS A TREATMENT FOR METASTATIC OSTEOGENIC SARCOMA IN CHILDREN.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
L-phenylalanine mustard (NSC-8806) administration in osteogenic sarcoma: an evaluation of dosage schedules.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Clear cell sarcoma (CCS), a rare malignant tumor with a predilection for young adults, is of poor prognosis. Recently however, boron neutron capture therapy (BNCT) with the use of p-borono-L-phenylalanine (BPA) for malignant melanoma has provided good results. CCS also produces melanin; therefore,
Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In the present study, we established a lung metastasis animal model of CCS and investigated the therapeutic effect of boron neutron capture therapy (BNCT) using p-borono-L-phenylalanine (L-BPA). Biodistribution data revealed
Boron neutron capture therapy (BNCT) selectively destroys human clear cell sarcoma in mouse model.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Clear cell sarcoma of tendons and aponeuroses (CCS) is a rare malignant tumor with no effective treatment. This study demonstrates the efficacy of BNCT with the use of human CCS-bearing nude mice. Groups A and C were administered saline, and groups B and D were injected with
Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Fifty-nine patients with melanoma or soft tissue sarcoma of the extremities underwent hyperthermic isolated limb perfusion utilizing cisplatin and wide local excision. Doses of cisplatin ranged from 0.75 to 2 mg/kg. The mortality and morbidity rates were 0 and 6.8 percent, respectively.
Boron neutron capture therapy for clear cell sarcoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Clear cell sarcoma of tendons and aponeuroses (CCS) is a rare, malignant tumor arising in lower extremities with no effective treatment other than wide surgical resection. Here described is a case of primary CCS in the peroneal tendon of the right foot of a 54-year-old woman enrolled to undergo
Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Comparison is made of the development of resistance to cyclophosphamide (CPA) and L-phenylalanine mustard (L-PAM), of cross-resistance, and chromosome counts, in Walker 256 (W256), rat sarcoma R3 (R3), leukemia L1210, and Ridgway osteogenic sarcoma. For development of resistance the single maximum
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Resistance of mouse M5076 (M5) ovarian reticular cell sarcoma to cyclophosphamide (CTX) was obtained in vivo by repeated drug treatment followed by transplantation of the regrowing tumor. After 16 passages, we obtained an M5 subline resistant to CTX (M5-CTX-16R). Median survival times were
Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Soft tissue sarcomas continue to present problems with both local control of disease and death from distant metastases after accepted surgical therapy. Multimodality management has been established in the literature to be superior to traditional therapy of wide excision or amputation. The results of
Role of the host in the variable chemotherapeutic response of advanced Ridgway osteogenic sarcoma.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
It is axiomatic that a given dose of an antitumor agent will not produce the same effect in 100% of the treated subjects. Numerous explanations regarding the sources of this heterogeneous response to drugs have been offered; however, there is a scarcity of experimental data allowing critical
Clinical and biological significance of an isozyme tumor marker--PLAP.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In 1930 the determination of serum alkaline phosphatase in patients with bone or liver disease ushered in the era of clinical enzymology. The association of elevated (bone) alkaline phosphatase in serum of patients with osteogenic sarcoma was the first evidence that tumor cells themselves produced
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
